Floatz logo

Spi-2012

Pharmacokinetics

Spectrum Pharmaceuticals, IncPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pharmacokinetics cohort.

Asset / SponsorPhaseRating
SULFAMETHOXAZOLE
Texas Tech University Health Sciences Center
Phase 4BB
Trimethoprim
Texas Tech University Health Sciences Center
Phase 4BB
Gemtuzumab Ozogamicin
Pfizer
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Guangzhou General Hospital of Guangzhou Military Command
Phase 4BB
Human Plasma-Derived Coagulation Factor Viii Concentrate
Beijing Children's Hospital
Phase 4BB

View all 30 →

Same molecule, other indications

Spi-2012 is also rated in:

neutropeniaDormant
BB
Indicative ·
68 / 100
View asset →
breast cancerDormant
B
Indicative ·
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →